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Introduction
A typical community pharmacy will
dispense medicines for around 80
patients with heart failure. With the
average age at diagnosis 76 years,
most of these patients will also be 
on medication for other chronic
conditions.
Any cardiovascular disease can
potentially lead to heart failure,
which shows itself as clinical
signs such as breathlessness,
fatigue and fluid retention.
Although heart failure is difficult
to define, it is easy to recognise
in clinical practice. There are two
main types of heart failure:
• Left ventricular systolic
dysfunction
This is when the left ventricle that
pumps the blood around the body works
less well. This module will focus 
on this type of heart failure.
• Heart failure with preserved ejection
fraction
This is usually associated with impaired
left ventricular relaxation. There is normal
or preserved left ventricular pumping. 
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To update community pharmacists on
medicines optimisation for patients 
with chronic heart failure. 
OBJECTIVES:
After studying this module you should be able to:
• Describe the classes, signs and symptoms of
chronic heart failure
• Discuss optimised therapies and classes of
medicines used to manage chronic heart failure
• Plan and conduct a medicines optimisation
consultation with a patient who has heart failure.
Welcome to the two hundred and thirty eighth module
in the Pharmacy Magazine Continuing Professional
Development Programme, which looks at the
management of heart failure.
Journal-based educational programmes are an
important means of keeping up to date with clinical 
and professional developments. Completion of this
module in the magazine or online will contribute to 
the nine pieces of CPD that must be recorded a year. 
Before reading this module, test your existing
understanding of the subject by completing the pre-test
at www.pharmacymagazine.co.uk. Then, after studying
the module in the magazine or online, work through 
the learning scenarios and post-test on the website.
Record your learning using your personal Pharmacy
Magazine online log or complete the form on pviii.
The RPS Faculty and advancing your
professional development
Pharmacy Magazine’s CPD programme can form part of your
professional development, providing you with essential
knowledge and skills. It can also be considered alongside
other activities for inclusion in your RPS Faculty portfolio. 
The RPS Faculty is a professional recognition programme
for all pharmacists in all sectors at all stages of their career
and involves assessment of a practice-based portfolio that
recognises their professional development.
This allows you to demonstrate to others your level of
attainment and stage of advanced practice. It also helps you
to identify what you need to know at different stages of your
career. Start your Faculty journey by accessing the portfolio
and tools at www.rpharms.com/Faculty.
This module is also online at 
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This module provides a summary of current
management of heart failure based on the most
recent NICE guideline: ‘Chronic heart failure:
management of chronic heart failure in adults 
in primary and secondary care (CG108)’, issued
in August 2010, and NICE technology appraisal
TA267 – ‘Ivabradine for treating chronic heart
failure’, which was issued in 2012.
On average, a GP will look after 30 patients
with heart failure and will suspect the condition
in a further 10 patients each year. Heart failure
is estimated to account for one million inpatient
bed days (equivalent to 2 per cent of all NHS
inpatient bed days) and 5 per cent of all
emergency medical admissions to hospital. 
The total cost of heart failure to the NHS may be
over £700m per year, or around 1.8 per cent of
the total NHS budget. In addition to the NHS
costs, the disease places a significant burden 
on other agencies (e.g. social services).
A patient’s quality of life is affected by the
physical limitation imposed by the disease and
the emotional problems that arise as a result.
The challenge is combined with managing 
other co-morbidities as well as dealing with
polypharmacy and potential side-effects from
multi-drug therapy.
Causes, pathophysiology and
prognosis
The commonest causes for functional
deterioration of the heart include:
• Coronary artery disease (myocardial
infarction, ischaemia)
• Hypertension
• Cardiomyopathy and congenital heart disease
• Arrhythmias (tachycardia and bradycardia)
• Alcohol
• Medication (including calcium antagonists,
anti-arrhythmics, cytotoxic drugs).
Chronic heart failure has two major comp-
onents: an abnormality of the heart itself and
the response of the body to the diminished
ability of the heart to function as a pump.
(Reduced function of the heart as a pump is
usually caused by an abnormality of the muscle,
rhythm, valves or pericardium.) 
The signs and symptoms of chronic heart
failure are mainly as a consequence of long-
term responses in the body to these two
components. For example, salt and water
retention is the result of abnormal function of
the kidney, while the shortness of breath and
fatigue are related to chronic changes in the
skeletal muscle.
Chronic heart failure is a dynamic situation
rather than a steady-state condition and, as
heart function changes, many patients develop
exacerbations. Many clinical features have 
been shown to have prognostic significance in
patients. For example, severity of symptoms,
exercise capacity, haemodynamics, plasma
hormone concentrations such as noradrenaline,
renin activity and B-type natriuretic peptide
(BNP) are all indicative in terms of prognosis. 
Signs and symptoms 
The classical symptoms of heart failure are
dyspnoea, ankle oedema and fatigue. Dyspnoea
may be due to respiratory disease (particularly
COPD) and therefore cannot be the only
criterion for the diagnosis of heart failure.
Orthopnoea (shortness of breath when lying
flat) and paroxysmal nocturnal dyspnoea 
(a sensation of shortness of breath that wakes
the patient after one to two hours of sleep) are
more likely to be related to heart failure. 
The clinical signs reflect the consequence 
of heart failure. For example, left ventricular
dilatation is reflected in signs of cardiomegaly;
fluid retention is reflected in signs of congestion
(ankle oedema, jugular venous distension,
pulmonary crackles); and low cardiac output 
in signs of poor perfusion.
Dyspnoea
Perhaps the most prominent symptom of heart
failure is breathlessness or dyspnoea. The
patient is aware of the increased respiratory
effort as an uncomfortable sensation of not
being able to get enough air.  
Chronic fatigue
The second cardinal feature of heart failure 
is chronic fatigue. Fatigue is a non-specific
symptom which, in the past, had been attributed
to the low cardiac output, but the mechanism is
now thought to be far more complex and poorly
understood. It is also likely that abnormalities of
the skeletal muscle and biochemistry contribute
to poor exercise tolerance and chronic fatigue.
Circulatory congestion
The third sign and symptom of chronic heart
failure is circulatory congestion, which shows
itself as the presence of neck vein distension. 
Pharmacy Magazine CPD modules
provide you with knowledge to help you to develop and advance 
your practice and can be recorded in your Faculty portfolio. 
Start your journey now by accessing the Faculty portfolio, tools 
and resources atwww.rpharms.com/Faculty
Working in association with
Management of heart failure causes a considerable drain on NHS resources
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A third heart sound and peripheral oedema are
highly characteristic of the heart failure syndrome.
Heart failure classification
The American College of Cardiology and
American Heart Association classify heart failure
based on structural changes and symptoms. 
The New York Heart Association (NYHA)
classification is used in determining the
inclusion and exclusion of patients in heart
failure clinical trials as well as routine diagnosis
and management (see Table 1). 
Following a cardiac examination to get an
accurate evaluation of the heart failure, further
clinical tests will be considered.
Routine laboratory tests include:
• Chest x-ray
Although a chest x-ray cannot be used on its
own to diagnose heart failure, it is important 
to help exclude other causes of shortness of
breath and to support a possible diagnosis of
heart failure. It is mainly useful for showing 
the magnitude of the heart enlargement
(cardiomegaly). 
• Echocardiography
This is the single most effective tool in con-
firming diagnosis of heart failure. It provides
information on wall thickness, valve action 
and ejection fraction estimated to reflect the
ventricular functioning of the heart. 
• Electrocardiogram
Electrocardiogram (ECG) is useful once a
diagnosis of heart failure has been confirmed 
(if it has not been performed already) as it 
may help determine the underlying cause. 
The specificity of an abnormal ECG for heart
failure is relatively poor, although patients with
heart failure may show abnormalities in the
Q wave, T wave and ST region. 
• Biochemistry
Investigations would usually include renal
function (urea and creatinine) and electrolytes
(particularly serum sodium and potassium). 
The investigations are used to exclude other
diagnoses and also include liver function and
thyroid function tests, fasting lipids and glucose.
They are also useful for baseline function prior
to starting therapy and also to monitor disease
progression.
• Natriuretic peptides (mainly B-type
natriuretic peptide)
Secreted from the ventricles in response to
volume expansion, B-type natriuretic peptide
(BNP) causes an increase in renal excretion of
sodium and water, and vasodilation. 
Low or normal BNP levels can be used to rule
out a diagnosis of heart failure. 
Raised levels are suggestive of heart failure
but are non-specific, so should be interpreted
alongside other investigations before a
diagnosis is reached. 
BNP levels can be used to assess cardiac
function – the higher the BNP levels, the poorer
the prognosis. 
• Haematological tests
These are used mainly to exclude anaemia and
any other causes.
Pharmacological treatment
There is a wealth of evidence from a large
number of high-quality clinical trials to support
the use of pharmacological therapy in all stages
of heart failure with left ventricular systolic
dysfunction, from asymptomatic left ventricular
systolic dysfunction to severe heart failure. 
Pharmacological treatment can improve the
quality of life by: 
• Improving symptoms or slowing their
deterioration
• Reducing admissions and re-admissions to
hospital 
• Reducing mortality.
Community pharmacists are well placed 
to support patients to derive the maximum
benefits from these evidence-based therapies 
by ensuring that:
• Correct evidence-based medicines are
prescribed
• Doses are up-titrated to the maximum
tolerated or target doses
• Patients are counselled on monitoring the
effectiveness of their medicines
• Patients are counselled on side-effects and
how to monitor and reduce them 
• Patients are supported to fit their medicines
around their daily routine 
You can complete this module online at
pharmacymagazine.co.uk and record your
learning outcomes and the impact on your
practice in your personal learning log
Stages of heart failure based on structure and damage to
heart muscle
Stage A
At high risk of developing heart failure.
No identified structural or functional abnormality; 
no signs or symptoms
Stage B
Developed structural heart disease that is strongly associated
with the development of heart failure, but without signs and
symptoms
Stage C
Symptomatic heart failure associated with underlying
structural heart disease
Stage D
Advanced structural heart disease and marked symptoms of
heart failure at rest despite maximal medical therapy
NYHA functional classification (based on symptoms and
physical activity)
Class 1
No limitation of physical activity.
Ordinary physical activity does not cause undue fatigue,
palpitations or dyspnoea
Class II
Slight limitation of physical activity.
Comfortable at rest but ordinary physical activity results in
fatigue, palpitations or dyspnoea
Class III
Marked limitation of physical activity.
Comfortable at rest but less than ordinary physical activity
results in fatigue, palpitations and dyspnoea
Class IV
Unable to carry out any physical activity without discomfort.
Symptoms at rest. If any physical activity is undertaken,
discomfort is increased

Table 1: The NYHA classification of the stages of heart failure
Guidelines from the European Society of Cardiology
define heart failure as a clinical syndrome in which
patients have the following features:
• Symptoms such as breathlessness at rest or with
exercise, fatigue, tiredness, ankle swelling
• Signs such as tachycardia, tachypnoea (rapid
breathing), pulmonary rales (crackles), pleural
effusion, raised jugular venous pressure, peripheral
oedema, hepatomegaly
• Objective evidence of structural or functional
abnormality of the heart at rest (cardiomegaly, third
heart sound, cardiac murmurs, abnormality of the
heart on echocardiography, raised natriuretic peptide
concentration).

Definition of heart failure
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• Patients are empowered to self-manage their
condition.
Pharmacists should also ensure they are able to
answer any concerns a patient may have.
Although the National Heart Failure Audit
(April 2010-March 2011) confirmed that there
had been an improvement in the use of key
treatments, such as ACE inhibitors and beta-
blockers, the use of beta-blockers in particular
remains far from optimal. While it was clearly
demonstrated that the number of recommended
disease modifying drugs a patient was
prescribed on discharge from hospital had a
significant impact on survival, not all patients
with heart failure receive all the medicines. 
This is particularly an issue in patients
discharged from non-cardiology wards. 
Pharmacists can screen therapies prescribed
for patients with heart failure post-discharge
and target those who were admitted to 
non-cardiology wards. 
All patients with heart failure should be
prescribed an ACEI and a beta-blocker licensed
for use in heart failure, unless contraindicated.
The doses should be up-titrated to the target
dose or maximum tolerated dose. Diuretics 
are prescribed to reduce symptoms of fluid
overload. The dose and combination of diuretics
are adjusted according to the patient’s fluid
status and symptoms. Patients are usually
empowered by providing them with a self-
management plan that clearly states when 
to increase and decrease their diuretic doses. 
It is important to emphasise that aldosterone
antagonists are usually prescribed at lower
doses and mainly used for their ‘aldosterone
antagonist’ effect, which is associated with
lower mortality in patients with heart failure,
rather than their diuretic effect, which is very
minimal at lower doses. 
It is important to be clear about the plan 
that was agreed with the patient in order 
not to provide confusing or contradictory
information. Liaising with the multidisciplinary
team looking after the patient is therefore
essential. This includes the heart failure nurses,
cardiology pharmacists and GPs. 
Diuretic therapy
Improving the management of fluid retention
can minimise symptoms of breathlessness 
due to congestion. Loop diuretics, such as
furosemide or bumetanide, are the main agents
used. Thiazide or thiazide-like diuretics are less
often used on their own in chronic heart failure
as they tend to produce weak diuresis and are
less effective when glomerular filtration rates
are less than 30mL/min. 
Metolazone, a thiazide-like diuretic, has been
withdrawn from the UK market, so the advice
from the British Society for Heart Failure is to
use bendroflumethiazide instead at a dose of
2.5mg. Higher doses (5mg or more) might be
necessary in patients with CrCl < 30mL/min.
The frequency of dosing may range from daily 
to once a week when used as part of augmented
diuresis (combining a loop diuretic with a
thiazide or thiazide-like drug). 
Electrolyte balance, particularly potassium,
should be monitored on a regular basis for all
patients with chronic heart failure on diuretic
therapy. Renal function should also be
monitored regularly to avoid worsening renal
impairment or acute renal failure.
During episodes of heart failure exacerbation
(or decompensation), gut oedema may reduce
absorption of tablets and patients may require
intravenous therapy in order to ensure 100 
per cent bioavailability and clinical effect. 
This will require admission to hospital, a
specialist heart failure outpatient setting for
treatment, or special IV community cardiac
services.
Diuretics improve symptoms of breathlessness
and exercise performance in patients with heart
failure. The NICE guideline recommends using
diuretics routinely for the relief of congestive
symptoms and fluid retention in heart failure,
titrated (up and down) according to need
following the initiation of subsequent therapies.
The daily and maximum dose of diuretics
recommended by NICE is shown in Table 2.
ACE inhibitors
ACE inhibitors improve survival in heart failure
patients with left ventricular systolic dys-
function. The benefit is significant in patients
with more severe left ventricular systolic
dysfunction or more severe symptoms although
there is a benefit in all patients in all the NYHA
classes. 
There is also good evidence to suggest that
ACE inhibitors reduce exacerbations of heart
failure and the risk of hospitalisation from 
the disease.
Identify if your area has a community cardiac service. 
• Which healthcare professionals are part of the
service? 
• How do they accept referrals? 
• Do they offer an IV service? 
• What help and support do they need from
community pharmacy?  

Activity
Drug
Loop diuretics
Furosemide
Bumetanide
Thiazide diuretics
Bendroflumethiazide
Indapamide
Metolazone*
*(withdrawn from the market, but
available from ‘special order’
manufacturers or specialist-importing
companies)
Potassium-sparing diuretics
Amiloride
Triamterene
Initial dose 
20-40mg
0.5-1mg
2.5mg
2.5mg
2.5mg
With ACE  (without ACE)
2.5mg (5mg)
25mg (50mg)
Maximum dose 
250-500mg
5-10mg
5mg
2.5mg
10mg
With ACE (without ACE)
20mg (40mg)
100mg (200mg)

Table 2: NICE recommendations for diuretics
Review the recent BNF, the NICE heart failure guidance and
‘chronic heart failure – ivabradine technology appraisal’ 
at www.nice.org.uk. Familiarise yourself with the
pharmacological therapies and dose optimisation required
for each class. How can you monitor and optimise
medication for the next 10 patients you see with chronic
heart failure?

Reflection exercise 1
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Many of the pathophysiological abnormalities
that characterise heart failure may be reversed
with ACE inhibitors. Their main effect is to block
the conversion of angiotensin I to angiotensin
II – a very potent vasoconstrictor that
stimulates the release of aldosterone, resulting
in sodium and water retention, and it has 
a direct effect on the heart muscle causing
enlargement of the heart (remodelling). 
ACE inhibitors are therefore arterial and
venous vasodilators that cause unloading of 
the heart. As a result, left ventricular mass and
cavity size is reduced. Left ventricular systolic 
function is improved. Skeletal muscle blood flow
is increased, which in turn improves exercise
capacity in patients.
ACE inhibitors affect the renal system via
neurohormonal pathways, preventing further
deterioration in cardiac function and worsening
of heart failure. They also reduce symptoms of
fatigue and breathlessness and improve exercise
capacity. ACE inhibitors should be initiated at a
low dose and titrated upwards at short intervals
(e.g. every two weeks) until the optimal
tolerated or target dose is achieved.
Angiotensin II receptor blockers
Angiotensin II receptor blockers (ARB) act 
by reducing renin-angiotensin activity through
inhibiting the angiotensin II receptor site. 
These agents are better tolerated than ACE
inhibitors but the evidence for their use in heart
failure is much weaker than that for ACE
inhibitors. ARBs should be reserved for patients
who are truly intolerant to ACE inhibitors and
not seen as “ACEI without the cough”.
The addition of an ARB can also be considered
for symptomatic chronic heart failure patients
who are already taking conventional therapy. 
Similar to ACE inhibitors, ARBs require careful
renal function monitoring but, unlike ACE
inhibitors, they do not block the breakdown 
of bradykinin and therefore do not show signs
of dry persistent cough as a side-effect. 
The CHARM-Alternative clinical trial
investigated the use of candesartan in chronic
heart failure patients intolerant of ACEI and
demonstrated that hospitalisation rates as well
as all-cause mortality were reduced significantly.
The trial showed that ARBs may be added to the
maximum tolerated dose of ACE inhibitor plus
beta-blocker if the patient is still symptomatic,
under specialist supervision. The combination
reduced cardiovascular death or hospitalisation
for heart failure with no effect on all-cause
mortality. That said, this approach is not used
much in clinical practice due to the increased
risk of hyperkalaemia and renal failure. 
Beta-blockers
Beta-blockers are started on the lowest dose
(e.g. bisoprolol 1.25mg daily) and gradually
increased while monitoring heart rate, blood
pressure and clinical status. Doses should 
be up-titrated at not less than two-weekly
intervals, aiming for the target dose or the
highest tolerated dose. 
This slow up-titration (NICE calls it “start
slow, go slow”) is due to the fact that heart
failure symptoms may be exacerbated during the
initial period of therapy and patients need to be
fully informed of the potential for this in order
to minimise anxiety. These symptoms, which
may include an increase in breathlessness and
ankle oedema, will subside with time. 
Some patients may require adjustment in 
the diuretic dose in order to control these
symptoms. NHS Clinical Knowledge Summaries
advises that “temporary deterioration occurs 
in 20-30 per cent of people during the titration
stage”. The effects of beta-blockers may take
some time to become apparent and Clinical
Knowledge Summaries advises that “symptoms
may improve slowly after starting treatment
(over three to six months)”.
Meta analysis of clinical trials with beta-
blockers (bisoprolol and carvedilol) in heart
failure has shown significant reduction in heart
Contact your GP surgery, community cardiac services team
or local hospital, and identify your local heart failure
clinics. How do they operate and what policies are in place
for heart failure drug therapy review and optimisation?

Reflection exercise 2
• Contact your hospital or community heart failure
service to identify what local guidelines they have
about the up-titration of ACEIs  
• Identify heart failure patients on your PMR. 
What combination of medicines should such 
patients be on? 
• Are these patients on optimal doses of ACEIs and 
beta-blockers? If not, why? Do they have a plan
agreed with the heart failure service? Do they have
low BP? Do they have low heart rate? If no clear
contraindication, should their doses be increased?

Practice activity
Enalapril
Lisinopril
Ramipril
Starting dose (mg)
2.5mg bd
2.5-5mg od
1.25-2.5mg od
Target dose (mg)
10-20mg bd
20-35mg od
10mg od

Table 3: Starting doses and target doses of some commonly used ACE inhibitors
in heart failure
Beta-blocker doses should be up-titrated slowly in heart failure
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rate and therefore survival benefits for the
disease. The SENIORS trial, where treatment 
of heart failure with nebivolol in the elderly 
(70 years) was evaluated, also was shown to
reduce morbidity. 
NICE guidelines recommend that both ACE
inhibitors and beta-blockers licensed for the
management of heart failure should be offered
to all patients with left ventricular systolic
dysfunction. These patients include older adults
and patients with peripheral vascular disease,
erectile dysfunction, diabetes mellitus,
interstitial pulmonary disease and chronic
obstructive pulmonary disease (COPD) without
reversibility. 
According to the NICE guideline, a patient 
who may already be on a beta-blocker for a 
co-morbidity, such as angina or hypertension,
should be switched to a beta-blocker that is
licensed for the management of heart failure.
Although NICE clearly recommends the use 
of beta-blockers there is sometimes reluctance
among GPs to prescribe them because of 
the history of side-effects. Pharmacists can
reinforce not only the need for beta-blockers 
but also the gradual increase in dose and can
offer practical support for patients.
Aldosterone receptor antagonists
Spironolactone and eplerenone act by blocking
aldosterone, thereby reducing water and 
salt retention. Spironolactone, added to
conventional therapy, reduces both mortality
and frequency of hospitalisation. The NICE
guidance recommends that a licensed
aldosterone antagonist may be added to the
treatment regimen in patients with class III or 
IV heart failure or those who have suffered a
myocardial infarction, if there are still symptoms
despite optimal therapy with an ACE inhibitor
plus beta-blocker. 
Since the publication of the NICE guidelines,
the EMPHASIS-HF trial (2011) has shown
benefit for the use of eplerenone in those with
mild heart failure (mainly NYHA classification II)
despite being on standard therapy.   
Patients on spironolactone should be
monitored for signs of renal dysfunction and
gynaecomastia. Hyperkalaemia is also carefully
monitored, in particular in combination therapy
with ACE inhibitors. 
Eplerenone is a newer aldosterone antagonist
with a better side-effect profile as it is less likely
to cause gynaecomastia. Other monitoring
requirements are the same as for spironolactone.
Eplerenone is licensed in post-myocardial
infarction patients with heart failure and as an
adjunct in chronic mild heart failure with left
ventricular ejection fraction ≤30 per cent.
Ivabradine
Ivabradine selectively and specifically inhibits
the cardiac pacemaker leading to a reduction 
in heart rate. According to the NICE 2012
technology appraisal, ivabradine is an option for
treating mild to severe stable chronic heart
failure, in combination with standard therapy –
beta-blockers, an ACEI, and an aldosterone
antagonist (unless contraindicated or not
tolerated). Patients should fulfil the following
additional criteria: a left ventricular ejection
fraction of ≤35 per cent and are in sinus rhythm
with a heart rate of ≥75 beats per minute. 
Ivabradine should be initiated by a heart
failure specialist after four weeks of stable
optimal standard therapy. Patients should be
monitored for bradycardia and heart rate at rest
should not be allowed to fall below 50 beats per
minute. If patients develop visual side-effects
described as transient enhanced brightness in 
a limited area of the visual field (phosphenes),
then caution should be exercised when driving
or using machines. Phosphenes were generally
reported to be of mild to moderate intensity and
the majority resolved during treatment.
Cardiac glycosides
Digoxin may be used in patients with heart
failure who are still symptomatic despite
optimised conventional therapy. Trials 
with digoxin in heart failure patients have
demonstrated no survival benefits but the rate 
of hospitalisation for worsening heart failure
was reduced. 
Digoxin is usually prescribed at low doses
without loading for stable patients in sinus
rhythm. Care should be taken in elderly patients
who should be monitored for signs of toxicity
such as nausea, confusion, disturbance of vision
and dysrhythmias.
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Alcohol consumption should be discussed with heart failure patients
What important drug and food interactions do you
need to check for when clinically validating a
prescription for ivabradine?

Practice activity
Consider the drug interactions for spironolactone and
eplerenone. What advice would you give to patients
taking them?

Practice activity
What information does your local hospital and heart failure
service provide to patients? Visit the British Heart
Foundation website (www.bhf.org.uk) and identify what
support and information is available for patients with
chronic heart failure.

Reflection exercise 3
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NICE guidelines for other drugs
The decision to prescribe or continue
amiodarone in patients with heart failure should
be reviewed regularly. Patients on amiodarone
should have a routine six-monthly clinical
review, including liver and thyroid function 
test and an assessment of side-effects.
Anticoagulation should be considered in
patients with heart failure in sinus rhythm if
there is a history of thromboembolism. Low
dose aspirin should be prescribed if heart failure
patients have atherosclerotic arterial disease
such as coronary heart disease.
Hydralazine plus isosorbide dinitrate can 
be used in those who cannot tolerate ACEI or
ARB, or as an add-on to standard treatment. 
Lifestyle advice for patients 
The following lifestyle advice should be given to
all patients with chronic heart failure:
• Strong recommendation to stop smoking and
referral to a smoking cessation clinic
• Alcohol consumption should be discussed and
those with alcohol-related heart failure should
abstain from drinking
• Annual influenza vaccination 
• Once-only vaccination against pneumococcal
disease 
• A supervised group exercise-based
rehabilitation programme 
• Salt restriction – patients should avoid a 
salt intake of greater than 6g per day (2.5g
sodium)
• Regular monitoring of weight and an
understanding of the common signs and
symptoms of worsening heart failure 
(e.g. increased shortness of breath with 
a decrease in exercise tolerance, weight gain
of more than 2kg in two days). 
The NICE Quality Standards for chronic heart
failure state that people with stable chronic
heart failure should receive a clinical assess-
ment at least every six months, including a
review of medication and measurement of 
renal function.
Pharmacy Magazine’s CPD modules are available on Cegedim Rx’s PMR systems, Pharmacy
Manager and Nexphase. Just click on the ‘Professional Information & Articles’ button within
Pharmacy KnowledgeBase and search by therapy area. Please call the Cegedim Rx helpdesk 
on 0844 630 2002 for further information.
This module is also online at 
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• Use your PMR to review the history of the medicines prescribed and dose changes
• Ask the patient/carer how they have been getting on with the medicines when the doses were increased
• Establish if there is an agreed management plan with a heart failure nurse/pharmacist
• Assess patient adherence and find out if they have any concerns about their medicines
• Reconcile medicines after discharge and check that the patient is clear about all changes to their medicines 
and that they have no concerns 
• Check for signs of dehydration and whether any increase in diuretic doses was temporary and not long-term
(especially augmented diuresis)  
• Look out for medicines with a high sodium content
• Check if the patient is using any OTC herbal remedies/supplements and if so whether suitable for use in heart failure
• Give a reminder on lifestyle advice
• Make sure your signposting list includes information on local exercise programmes for people with heart failure 
(may be provided as part of cardiac rehab)
• Watch out for worsening symptoms – NHS Clinical Knowledge Summaries advises that patients should “seek medical
advice if they experience a rapid deterioration in symptoms, such as tiredness, fatigue or breathlessness. Worsening
symptoms can usually be controlled by adjusting other medications, and beta-blockers should never be stopped
without consulting a healthcare professional”.

Points to bear in mind with MURs on heart failure patients
British Heart Foundation
Heart Help Line: 0300 330 3311 
Web: www.bhf.org.uk
Heart UK
Helpline: 0845 450 5988 
Web: www.heartuk.org.uk
British Cardiac Patients Association
Helpline: 01223 846845 
Web: www.bcpa.co.uk

Further information and support
You are interested in providing a service to help with the
optimisation of medication in patients with chronic heart
failure. How would you establish the need for such a
service in your pharmacy?
Contact your hospital and identify any members of 
the pharmacy team who are part of cardiology services.
Discuss this with the community cardiac services team. 

Reflection exercise 4
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HEART FAILURE
1. Patients with heart failure
should be advised to:
a. Use potassium-based salt
instead of sodium salt
b. Avoid a salt intake of greater
than 6g per day
c. Increase their intake of food
with a naturally high
potassium content 
d. Limit fluid intake to 1L a day
2. Which is TRUE?When
advising patients to
recognise signs of
deterioration: 
a. They should weigh themselves
every other day
b. Weight gain of more than 2kg
in two days requires no action 
c. They should be made aware 
of the signs and symptoms of
deterioration 
d. They should never change 
the dose of their diuretics on
their own
3. Which statement is FALSE?
a. Current evidence shows that
an aldosterone antagonist can
be initiated in patients with a
NYHA II 
b. ARBs may be used in patients
intolerant to ACE inhibitors
c. Aldosterone antagonists 
have been shown to reduce
mortality and hospitalisation 
d. ACE inhibitors should be
titrated at intervals of two 
to three months in order to
avoid worsening of heart
failure symptoms
4. Which is the least likely to
be present in patients with
chronic heart failure?
a. Fatigue
b. Breathlessness
c. Ankle oedema
d. Muscular chest pain
5. Which drug has no effect in
improving survival but may
be useful in symptomatic
patients who are optimised
on conventional therapies?
a. Ramipril
b. Digoxin
c. Candesartan
d. Bisoprolol
6. Which side-effect is more
likely to be associated with
spironolactone than with
eplerenone?
a. Hyperkalaemia
b. Hypokalaemia
c. Gynaecomastia 
d. Diarrhoea
7. Which of the following is
most likely to cause rapid
electrolyte imbalance?
a. Bendroflumethiazide 
b. Furosemide
c. Furosemide and metolazone
d. Ramipril
8. Which statement is FALSE?
a. Bisoprolol, carvedilol and
nebivolol are the only 
beta-blockers licensed 
for heart failure
b. A stable patient taking atenolol
for angina who then develops
heart failure should stay on
the same beta-blocker
c. Temporary deterioration in
heart failure symptoms occurs
in up to one in three patients
when a beta-blocker is
introduced
d. Treatment with a beta-blocker
may take six months for the
full improvement to be seen
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